Request Demo
Last update 03 Jan 2026
Insulin Degludec biosimilar(Zhuhai United Laboratories)
Last update 03 Jan 2026
Overview
Basic Info
Drug Type Biosimilar, Peptide Hormone |
Synonyms- |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 4857
The sequence is quoted from: *****
Sequence Code 91440
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Insulin Degludec biosimilar(Zhuhai United Laboratories)CTR20220152
多中心、随机、开放、阳性对照的Ⅲ期临床试验比较联邦制药德谷胰岛素注射液和诺和达®治疗2 型糖尿病的有效性和安全性
[Translation] A multicenter, randomized, open, positive-controlled Phase III clinical trial comparing the efficacy and safety of United Lab's insulin degludec injection and Tresiba® in the treatment of type 2 diabetes
ChiCTR2200056996
A randomized, open, two-period, self-cross-control design, using glucose clamp technology to evaluate pharmacodynamics and safety of insulin degludec injection
CTR20212703
随机、开放、两周期、自身交叉对照设计，采用葡萄糖钳夹技术评价空腹状态下德谷胰岛素注射液与“诺和达®”在中国健康成年男性受试者中药效学和安全性比对试验
[Translation] A randomized, open-label, two-period, self-crossover controlled trial using glucose clamp technology to evaluate the pharmacodynamics and safety of degludec injection and Tresiba® in healthy Chinese adult male subjects under fasting conditions
100 Clinical Results associated with Insulin Degludec biosimilar(Zhuhai United Laboratories)
Login to view more data
100 Translational Medicine associated with Insulin Degludec biosimilar(Zhuhai United Laboratories)
Login to view more data
100 Patents (Medical) associated with Insulin Degludec biosimilar(Zhuhai United Laboratories)
Login to view more data
100 Deals associated with Insulin Degludec biosimilar(Zhuhai United Laboratories)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 3 | China | 28 Feb 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free